Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
Investor Centre
Investor Centre
>
ASX Announcements
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
28 Apr 2021
Preclinical Data Support Development AMP945 Pancreatic Cancer
28 Apr 2021
Quarterly Report and Shareholder Update
22 Apr 2021
Initial Director's Interest Notice - Jane Bell
22 Apr 2021
Shareholder Update and Presentation
20 Apr 2021
ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH
15 Apr 2021
Amplia Completes Dosing in Phase 1 Clinical Study of AMP945
12 Apr 2021
Amplia Appoints New Non-Executive Director
25 Mar 2021
Change of Registered Office and Principal Place of Business
24 Mar 2021
Appendix 2A - Exercise of Options
18 Mar 2021
Amplia and Garvan Institute Enter Collaboration Agreement
Previous
1
2
3
4
5
6
7
8
9
Next
